These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33570654)

  • 1. The use of luspatercept for thalassemia in adults.
    Cappellini MD; Taher AT
    Blood Adv; 2021 Jan; 5(1):326-333. PubMed ID: 33570654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
    Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
    N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.
    Piga A; Perrotta S; Gamberini MR; Voskaridou E; Melpignano A; Filosa A; Caruso V; Pietrangelo A; Longo F; Tartaglione I; Borgna-Pignatti C; Zhang X; Laadem A; Sherman ML; Attie KM
    Blood; 2019 Mar; 133(12):1279-1289. PubMed ID: 30617198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
    Taher AT; Cappellini MD; Kattamis A; Voskaridou E; Perrotta S; Piga AG; Filosa A; Porter JB; Coates TD; Forni GL; Thompson AA; Tartaglione I; Musallam KM; Backstrom JT; Esposito O; Giuseppi AC; Kuo WL; Miteva D; Lord-Bessen J; Yucel A; Zinger T; Shetty JK; Viprakasit V;
    Lancet Haematol; 2022 Oct; 9(10):e733-e744. PubMed ID: 36007538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
    Garbowski MW; Ugidos M; Risueño A; Shetty JK; Schwickart M; Hermine O; Porter JB; Thakurta A; Vodala S
    Am J Hematol; 2024 Feb; 99(2):182-192. PubMed ID: 37782758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
    Chen N; Kassir N; Laadem A; Giuseppi AC; Shetty J; Maxwell SE; Sriraman P; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
    J Clin Pharmacol; 2021 Jan; 61(1):52-63. PubMed ID: 32696522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
    Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
    N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
    Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
    Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
    Cappellini MD; Taher AT; Piga A; Shah F; Voskaridou E; Viprakasit V; Porter JB; Hermine O; Neufeld EJ; Thompson AA; Tang D; Yucel A; Lord-Bessen J; Yu P; Guo S; Shetty JK; Miteva D; Zinger T; Backstrom JT; Oliva EN
    Eur J Haematol; 2023 Jul; 111(1):113-124. PubMed ID: 37095595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luspatercept: A Gigantic Step in the Treatment of Transfusion-Dependent β-Thalassemia Patients-a Quick Review.
    Darvishi-Khezri H; Karami H
    Adv Ther; 2021 Apr; 38(4):1732-1745. PubMed ID: 33661441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
    Kang C; Syed YY
    Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.
    Musallam KM; Taher AT; Kattamis A; Kuo KHM; Sheth S; Cappellini MD
    Drug Des Devel Ther; 2023; 17():1583-1591. PubMed ID: 37255740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia.
    Delgado J; Voltz C; Stain M; Balkowiec-Iskra E; Mueller B; Wernsperger J; Malinowska I; Gisselbrecht C; Enzmann H; Pignatti F
    Hemasphere; 2021 Aug; 5(8):e616. PubMed ID: 34291195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.
    Guerra A; Hamilton N; Rivera A; Demsko P; Guo S; Rivella S
    Am J Hematol; 2024 Jul; 99(7):1300-1312. PubMed ID: 38659383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of luspatercept to treat ineffective erythropoiesis.
    Kubasch AS; Fenaux P; Platzbecker U
    Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luspatercept, a two-edged sword in beta-thalassemia-associated paravertebral extramedullary hematopoietic masses (EHMs).
    Alashkar F; Klump H; Lange CP; Proske P; Schüssler M; Yamamoto R; Carpinteiro A; Berliner CA; Schlosser TW; Röth A; Reinhardt HC
    Eur J Haematol; 2022 Dec; 109(6):664-671. PubMed ID: 36045599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luspatercept for β-thalassemia: beyond red blood cell transfusions.
    Taher AT; Cappellini MD
    Expert Opin Biol Ther; 2021 Nov; 21(11):1363-1371. PubMed ID: 34404288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life experience with luspatercept in transfusion-dependent β-thalassemia.
    Roccotelli D; Grande D; Cicco G; Palma A; Longo MC; Albano F; Vitucci A; Musto P
    Ann Hematol; 2023 Oct; 102(10):2965-2967. PubMed ID: 37498329
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review.
    Dighriri IM; Alrabghi KK; Sulaiman DM; Alruwaili AM; Alanazi NS; Al-Sadiq AA; Hadadi AM; Sahli BY; Qasem BA; Alotaibi MT; Asiri TT; Majrashi SM; Alotibia NT; Alhamyani AT; Alharbi AA
    Cureus; 2022 Nov; 14(11):e31570. PubMed ID: 36540460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.